Cardigant Medical

CARDIGANT MEDICAL, a development-stage biotechnology company, focuses on developing novel bio-compounds and methods for the localized treatment of acute coronary syndrome, carotid artery stenosis, and aortic valve stenosis. It plans to treat atherosclerosis and plaque stabilization through systemic and localized delivery of high-density lipoprotein (HDL)-targeted macromolecular therapies. The company’s lead drug product is based on the AAPOA-1 protein, which plays a unique role in lipid metabolism.